AR-703 show positive result

AR-703 attaches to the ‘S2’ stalk region of coronavirus spike proteins which causes viral fusion and entry into host cells.

Created to have a durable impact, AR-701 is anticipated to offer substantial drug levels for up to a year from preventive or therapeutic treatment.

Furthermore, it binds to the Omicron variant with the same efficiency as the Wuhan strain of the virus.

Using live coronaviruses in in vitro neutralisation studies, the antibody cocktail attained wider, potent neutralisation against all viral variants as well as SARS, MERS, and the common cold betacoronaviruses.

AR-701’s wide-ranging efficacy is supported by in vivo data from several animal challenge models that are extensively utilised to assess Covid-19 therapies.

Delivering the AR-701 cocktail parenterally, either as a monotherapy or in combination, eliminated the Wuhan viral strain from the lungs of Covid-19 infected mice.